The entorhinal cortex (EC) plays a critical role in the pathogenesis of [cognitive impairment](/mechanisms/cognitive-decline) in Parkinson's disease (PD) and Parkinson's disease with dementia (PDD). While classically considered a disease of the [substantia nigra](/brain-regions/substantia-nigra), PD involves widespread cortical pathology, with the entorhinal cortex serving as a key site of [alpha-synuclein](/proteins/alpha-synuclein) deposition and associated [neurodegeneration](/diseases/neurodegeneration). This page examines the patterns of EC pathology in PD, its relationship to [cognitive decline](/mechanisms/cognitive-decline), and the circuit dysfunction that underlies the high prevalence of dementia in long-standing PD.
The entorhinal cortex (EC) plays a critical role in the pathogenesis of [cognitive impairment](/mechanisms/cognitive-decline) in Parkinson's disease (PD) and Parkinson's disease with dementia (PDD). While classically considered a disease of the [substantia nigra](/brain-regions/substantia-nigra), PD involves widespread cortical pathology, with the entorhinal cortex serving as a key site of [alpha-synuclein](/proteins/alpha-synuclein) deposition and associated [neurodegeneration](/diseases/neurodegeneration). This page examines the patterns of EC pathology in PD, its relationship to [cognitive decline](/mechanisms/cognitive-decline), and the circuit dysfunction that underlies the high prevalence of dementia in long-standing PD.
According to the Braak staging system for alpha-synuclein pathology in PD, the entorhinal cortex becomes involved in Stage III of disease progression[@braak2003]. At this stage, pathology reaches the olfactory bulb, pontine nuclei, and the entorhinal cortex. The EC represents a critical transition zone where pathology spreads from brainstem and olfactory structures to the limbic archicortex.
The pattern of alpha-synuclein deposition in the EC follows a characteristic progression. Initially, Lewy bodies and Lewy neurites appear in the superficial layers (I-II), which contain the majority of intrinsic [neurons](/cell-types/neurons). The deeper layers (IV-VI) become involved later, corresponding to the spread of pathology to the allocortical regions.
In Parkinson's disease, the EC shows several pathological features distinct from those seen in [Alzheimer's disease](/diseases/alzheimers-disease):
The severity of EC pathology correlates with disease duration and clinical stage. Patients with PDD show significantly more severe alpha-synuclein pathology in the EC compared to non-demented PD patients. This correlation suggests that the EC may serve as a predictor of cognitive outcome, with early EC involvement portending higher risk of subsequent dementia[@halliday2014].
The entorhinal cortex is critically involved in the cognitive deficits that affect 50-80% of long-standing PD patients. Cognitive impairment in PD ranges from mild cognitive impairment (PD-MCI) to overt dementia (PDD), with the EC playing a central role in both conditions.
Neuropathological studies consistently demonstrate that EC alpha-synuclein burden correlates with the severity of dementia in PD[@hurtig2000]. Patients with high EC pathology scores show earlier onset and more severe cognitive decline. This relationship remains significant even after controlling for comorbid AD pathology, confirming the independent contribution of alpha-synuclein to cognitive impairment.
The EC contributes to cognitive impairment through multiple mechanisms:
A significant proportion of PD patients show comorbid AD pathology, particularly in older individuals. The combination of alpha-synuclein and tau/[amyloid](/proteins/amyloid-beta) pathology in the EC produces synergistic effects on cognitive decline. Patients with both pathologies show more severe cognitive impairment than those with either pathology alone, suggesting additive or synergistic mechanisms.
Studies examining the EC in PD reveal that approximately 30-50% of PD patients have sufficient AD pathology to meet criteria for comorbid AD diagnosis. These patients show more rapid progression to dementia and more severe cognitive deficits, highlighting the importance of assessing EC pathology comprehensively.
Alpha-synuclein pathology in the EC disrupts its connectivity with downstream hippocampal regions. The perforant path, originating in layer II EC neurons and terminating in the dentate gyrus, shows reduced integrity in PD patients with cognitive impairment. Diffusion tensor imaging demonstrates reduced fractional anisotropy in the perforant path, correlating with memory performance.
Functional connectivity studies reveal altered EC-hippocampal interactions in PD. Resting-state fMRI shows both hyperconnectivity in early stages (potentially compensatory) and hypoconnectivity in later stages (reflecting neurodegeneration). The transition from hyper- to hypo-connectivity may mark the onset of cognitive decline.
The EC receives dopaminergic input from the ventral tegmental area and substantia nigra pars compacta, which modulates its processing of memory-related information. In PD, dopaminergic denervation of the EC likely contributes to cognitive dysfunction. The cholinergic system, arising from the nucleus basalis of Meynert, also projects to the EC and is affected in PD, potentially exacerbating memory impairment.
Studies examining neurotransmitter systems in the PD EC demonstrate reduced dopaminergic, cholinergic, and noradrenergic markers[@kalaitzakis2013]. This multi-transmitter deficit likely produces more severe cognitive impairment than single-system involvement, consistent with the complex neuropsychological profile of PDD.
Beyond EC-hippocampal circuits, PD pathology affects broader cortical networks. The EC shows disrupted connectivity with default mode network regions, particularly the posterior cingulate cortex. This disconnection may contribute to the attentional deficits and executive dysfunction seen in PD cognitive impairment.
The pattern of network disruption in PD differs from AD, with PD showing more prominent involvement of dorsal attention and executive networks, while AD preferentially affects the default mode network. These differences may explain the distinct cognitive profiles of the two conditions.
The EC provides potential biomarker targets for PD-related cognitive impairment:
Several strategies target EC pathology in PD:
The EC's role in PD cognitive impairment has several clinical implications: